 EDISON, NJ ACCESSWIRE January 5, 2021 Hepion Pharmaceuticals, Inc. NASDAQ:HEPAHepion, a clinical stage biopharmaceutical company focused on Artificial Intelligence AI-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis NASH and liver disease, announced today that management will participate in two virtual investor conferences in January. H.C. Wainwright BioConnect 2021 Conference January 11-14, 2021: Hepions pre-recorded presentation will be available for approximately 90 days on its website at under Events in the Investors section, beginning on Monday, January 11, 2021. 